ArticleHepatobiliary surgery and nutrition2026
Impact of metabolic dysfunction-associated steatotic liver disease on long-term prognosis in hepatocellular carcinoma patients undergoing hepatectomy.
Article in Hepatobiliary surgery and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has been recognized as an accurate reflection of the pathogenesis of fatty liver disease by a consensus document. However, the relationship between MASLD and the prognosis of hepatocellular carcinoma (HCC) patients receiving hepatectomy remains unclear. The aim of this study is to investigate whether MASLD affects the long-term prognosis of HCC patients undergoing hepatectomy. Methods: A multivariate Cox proportional hazards model and a propensity score matching (PSM) analysis were implemented to ensure equal baseline characteristics. The Kaplan-Meier survival curves were employed for prognosis comparison between the two groups. Results: This study involved 909 HCC patients who underwent hepatectomy between January 2011 and December 2017 at the West China Hospital of Sichuan University, including 97 patients with MASLD (MASLD group) and 812 patients without MASLD (non-MASLD group). According to the multivariate analysis, patients in the MASLD group showed worse recurrence-free survival (RFS) [hazard ratio (HR) =1.23; 95% confidence interval (CI), 1.13-1.72; P=0.03] and overall survival (OS) (HR =2.04; 95% CI, 1.06-2.73; P=0.03) than those in the non-MASLD group. After conducting a PSM analysis, Kaplan-Meier survival curve analysis disclosed significant differences in both the RFS and OS between the two groups (P=0.02 and P=0.01, respectively). All results showed that MASLD had a poor long-term prognosis for HCC patients undergoing hepatectomy. Conclusions: In summary, our study suggests that MASLD might be a risk factor for the OS and RFS in HCC patients who underwent hepatectomy through multivariate analysis and PSM analysis. These findings indicate that preoperative diagnosis of MASLD in HCC patients holds crucial significance in guiding the long-term prognosis of patients after hepatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.